Physician profile
Rex Figy
NPI 1861492357
$3,216.92
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.41 · 2020: $23.82 · 2021: $659 · 2022: $1,245 · 2023: $883 · 2024: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $508.08 | 2021-2024 | |
| Novo Nordisk INC | $496.95 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $272.42 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $182.57 | 2021-2024 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.61 | 2019-2022 | |
| Lilly USA, LLC | $161.54 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.45 | 2021-2024 | Xifaxan |
| Astellas Pharma US INC | $128.04 | 2021-2024 | Veozah |
| Welch Allyn | $117.71 | 2021 | |
| Baxter Healthcare | $117.71 | 2022 | |
| Glaxosmithkline, LLC. | $114.62 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Biogen, INC. | $94.92 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.49 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $53.97 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.46 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $46.04 | 2021-2022 | |
| Axsome Therapeutics, INC. | $44.66 | 2024 | Sunosi, Auvelity |
| Biohaven Pharmaceuticals, INC. | $41.57 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $36.63 | 2022 | |
| Exact Sciences Corporation | $34.14 | 2023-2024 | Cologuard Collection Kit |
| Endo Pharmaceuticals INC. | $32.90 | 2021 | |
| Abbott Laboratories | $32.62 | 2021-2022 | |
| Amgen INC. | $32.49 | 2022-2023 | Prolia, Evenity |
| Almatica Pharma LLC | $30.83 | 2021 | |
| Idorsia Pharmaceuticals US INC | $30.32 | 2022-2023 | Quviviq |
| Shield Therapeutics INC | $28.31 | 2023 | Accrufer |
| Sunovion Pharmaceuticals INC. | $23.99 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.29 | 2023 | Eliquis |
| Dexcom, INC. | $18.87 | 2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $17.04 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.45 | 2022 | |
| Mylan Specialty L.P. | $12.86 | 2023 | Yupelri |
| Sumitomo Pharma America, INC. | $12.37 | 2023 | Gemtesa |
| Corium, LLC | $12.00 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rex Figy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.